Abiopharma

🔍 MORRISSEY MICHAEL (Director)

Company: EXELIXIS, INC. (EXEL)

Report Date: 2026-01-15

Detailed Transactions and Holdings:

• Acquired 548,073 shares of Common Stock (Direct)
  Date: 2026-01-15 | Code: A | equity_swap_involved: 0 | shares_owned_after: 1,964,765.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
• Sold 139,524 shares of Common Stock at $45.23 per share (Direct)
  Date: 2026-01-15 | Code: F | equity_swap_involved: 0 | shares_owned_after: 1,825,241.00 | transaction_form_type: 4 | Footnotes: F4, F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-15 | Code: H | nature_of_ownership: By Trust | shares_owned_after: 1,714,404.00 | Footnotes: F5
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-15 | Code: H | nature_of_ownership: By 401(k) | shares_owned_after: 17,728.00 | Footnotes: F6

Footnotes:

• F1: On April 3, 2023, the Reporting Person was granted a performance-based restricted stock unit award ("PSU") under the Exelixis, Inc. 2017 Equity Incentive Plan covering 313,185 shares of common stock (such shares, the "Target Shares"). The PSU generally vests as follows: (i) 50% of the eligible Target Shares vest upon the Compensation Committee's (the "Committee") certification of achievement of certain performance criteria; and (ii) 50% of the eligible Target Shares vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. In addition, the PSU provides for vesting of up to a maximum of 175% of the Target Shares depending on the timing and level of achievement of the performance criteria provided for under the PSU.
• F2: On January 15, 2026, the Committee determined that certain performance criteria had been achieved, resulting in the Reporting Person's eligibility to vest up to 175% of the Target Shares subject to the PSU (such shares, the "Achieved Shares"). Accordingly, the Committee's certification on January 15, 2026 resulted in the immediate vesting of 50% of the Achieved Shares, and the remaining 50% of the Achieved Shares will vest on February 15, 2027, subject to the Reporting Person's continuous service through that date.
• F3: Includes 1,690,729 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs") and PSUs granted to the Reporting Person on March 31, 2025 ("One-Time Award PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each One-Time Award PSU represents a contingent right to receive one share of Common Stock.
• F4: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of the PSUs awarded on April 3, 2023, for which the Committee certified that Exelixis, Inc. had achieved certain performance criteria on January 15, 2026.
• F5: Shares held by Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Living Trust dated July 21, 1994, as amended.
• F6: Represents shares of Common Stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of January 14, 2026.